Acetylcysteine effervescent tablets for the treatment of pulmonary fibrosis, but the effect of a single drug is generally less than ideal.
Pulmonary fibrosis is a disease of unknown etiology, characterized by fibrotic proliferation of the interstitial lungs, and the current clinical treatment of IPF is mainly based on glucocorticoids, immunosuppressants, cytotoxic drugs and so on.
Acetylcysteine can scavenge oxygen free radicals, thus reducing the damage of oxygen free radicals to alveolar epithelial cells, and then inhibit fibroblast proliferation and differentiation caused by pulmonary fibrosis, but the effect of single use of the drug is less than ideal.
Acetylcysteine effervescent tablets are generally suitable for the treatment of patients with chronic respiratory infections such as chronic obstructive pulmonary disease and bronchitis who secrete a large amount of thick and sticky sputum. Occasionally, allergic reactions such as urticaria and bronchospasm may occur after administration, and adverse reactions such as nausea, vomiting, headache, tinnitus and tachycardia may also occur. It is contraindicated for those who are allergic to the drug and those who have phenylketonuria.
Patients who want to use acetylcysteine effervescent tablets for pulmonary fibrosis are advised to consult a professional doctor to avoid blind use.